Ketamine and Esketamine Therapy in Affective Disorders: A Comprehensive Review of Mechanisms, Clinical Evidence, Safety, and Future Directions

Abstract

Major Depressive Disorder (MDD) and Bipolar Depression represent significant global health burdens because about one-third of patients who receive standard monoaminergic antidepressant treatment fail to achieve remission. The population with Treatment-Resistant Depression (TRD) needs assistance because they deal with dangerous suicide risks and struggle with their daily activities. The review delivers an extensive assessment of ketamine and esketamine as glutamatergic modulators which medical professionals use to treat affective disorders. The study investigates the N-methyl-D-aspartate (NMDA) receptor antagonism mechanism together with clinical efficacy results from essential randomized controlled trials (RCTs) and drug distribution information and safety issues which include dissociation and cystitis and actual therapeutic use in medical practice. Research shows that intravenous (IV) ketamine at sub-anesthetic levels produces quick antidepressant results which start within hours for patients who do not respond to regular treatments. Esketamine received regulatory approval as an intranasal treatment for TRD and MDD with acute suicidal ideation because of the evidence from the TRANSFORM and SUSTAIN trial programs. The two medications show treatment effectiveness but they need continuous observation because patients experience dissociation and sedation and they have a risk of drug misuse. The conclusion states that Ketamine and esketamine develop a new psychiatric treatment method which replaces current monoamine hypothesis treatments with neuroplasticity-based therapies. The emergency treatment provides immediate results for dangerous medical situations but scientists need to prove its long-term safety track record and create successful methods for ongoing treatment maintenance.

Keywords

Ketamine, Esketamine, Treatment-resistant depression, NMDA antagonists, Rapid antidepressant

Introduction

Affective disorders, particularly Major Depressive Disorder (MDD) and Bipolar Depression, rank among the most common causes of disability throughout the world. The existing pharmacological treatments for monoaminergic systems (serotonin, norepinephrine, and dopamine) face two major problems which include extended time before treatment shows results and high rate of treatment failure [1,2]. The STAR*D study demonstrated that Treatment- Resistant Depression (TRD) remission rates decrease after every treatment attempt ends in failure.[3] During its 50-year period of dominance the monoamine hypothesis served as the primary framework for antidepressant research. The scientific breakthrough occurred in early 2000s when researchers found that even a single sub-anesthetic dose of the dissociative anesthetic ketamine could provide strong antidepressant effects which lasted for several hours. [4].

The research outcomes led scientists to investigate the glutamatergic system which operates as the primary neurotransmitter system in mammal brain functions. The rapid-acting antidepressants category begins with ketamine because it restores synaptic functions which chronic stress has impaired throughout the study [5]. The pharmaceutical industry developed S-enantiomer esketamine after intravenous racemic ketamine demonstrated successful results through its off-label applications. Esketamine which functions as an intranasal medication became the first glutamatergic modulator to receive FDA and EMA approval in 2019 for treating TRD and later for managing depressive symptoms in adults who experience acute suicidal ideation or behaviour [6]. The review will combine existing research by examining both ketamine and esketamine through their complex neurobiological mechanisms and their different pharmacokinetic properties and their clinical effectiveness across various populations and their required safety monitoring procedures which enable proper usage.

2. Affective Disorders: Overview

Major Depressive Disorder (MDD) manifests through ongoing depressive symptoms which include anhedonia and cognitive/vegetative symptoms. The pathophysiology involves atrophy of neurons in the prefrontal cortex (PFC) and hippocampus, areas critical for mood regulation [7]. The combination of chronic stress and depression results in decreased brain-derived neurotrophic factor (BDNF) production, which causes synaptic deterioration.

Bipolar Depression treatment requires special solutions because typical antidepressants increase the risk of causing manic episodes. Ketamine works as an effective treatment for bipolar depression when it is used together with mood stabilizers because it does not increase the risk of mania development.[8] People who experience Treatment-Resistant Depression (TRD) because they cannot find relief from their symptoms after trying two different antidepressant medications. TRD constitutes a serious mental health condition because its patients experience higher rates of comorbidity together with hospitalization and suicide.[9] The specific population represents the main medical need which requires ketamine and esketamine treatments.

3. Ketamine & Esketamine: Drug Profile

3.1 Ketamine

RS-ketamine exists as a racemic compound which contains equal amounts of R(-)-ketamine and S(+)-ketamine. The substance belongs to the class of arylcyclohexylamines because it shares structural similarities with phencyclidine (PCP). The substance first emerged as an anesthetic in 1962 which medical professionals later approved for use in surgical settings after FDA authorization in 1970 [10]. The United States classifies the substance as a Schedule III controlled substance because people can misuse it and experience dissociative effects. The psychiatric field uses the substance for off-label applications which doctors administer through intravenous methods yet they are studying its delivery through intramuscular and oral and subcutaneous methods.

3.2 Esketamine

The S(+)-enantiomer of ketamine exists as esketamine. The S(+) enantiomer shows approximately three to four times greater NMDA receptor binding power when compared to the R(-)-enantiomer [11]. The more powerful drug requires less amount for achieving identical receptor binding results. Esketamine nasal spray was developed to deliver a non-invasive treatment solution which replaces intravenous therapy while preventing first-pass metabolism that affects oral medications. The treatment received approval for use together with an oral antidepressant medication.

4. Mechanism of Action

The dual antidepressant effects of both ketamine and esketamine operate through a mechanism which functions independently from monoaminergic drug pathways. The N-methyl-D-aspartate (NMDA) receptor serves as the main target because it functions as an ionotropic glutamate receptor.

• NMDA Receptor Antagonism & The Glutamate Burst:

Ketamine acts as a non-competitive antagonist because it attaches to the phencyclidine site of the NMDA receptor channel with strong binding power. The "disinhibition hypothesis" which scientists currently accept asserts that ketamine blocks NMDA receptors primarily on GABAergic interneurons [12]. The interneurons maintain uninterrupted inhibitory control throughout the entire range of excitatory pyramidal neuron activity. The drug ketamine interrupts this inhibitory mechanism which results in a temporary increase of glutamate release in the medial prefrontal cortex (mPFC) [13].

• AMPA Receptor Activation:

The presence of increased extracellular glutamate results in the activation of $\alpha$-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptors because NMDA receptors remain blocked from binding the glutamate. The research shows that blocking AMPA receptors results in the complete loss of ketamine's ability to produce antidepressant results because the study demonstrates that this relationship causes a loss of AMPA-to-NMDA activity [14].

• Intracellular Signaling (mTOR & BDNF):

AMPA receptor activation causes postsynaptic neurons to become depolarized which leads to the activation of voltage-gated calcium channels. The calcium influx activates the mammalian target of rapamycin (mTOR) signaling pathway while it triggers BDNF release [15]. The cascade triggers fast synaptic protein production which includes PSD-95 and GluR1 to support synaptogenesis and restore dendritic spine loss caused by chronic stress [16].

• Alternative Hypotheses:

Current research shows that hydroxynorketamine (HNK) acts as a ketamine metabolite. The preclinical data indicates that (2R,6R)-HNK produces antidepressant effects through its direct activation of AMPA receptors which does not require NMDA receptor inhibition but this theory needs further proof in human studies [17]. Ketamine reduces bursting activity in the lateral habenula which operates with excessive activity during depression to block reward pathways [18].

5. Pharmacokinetics

The pharmacokinetics of a drug require investigation because it delivers vital data which enables clinicians to determine appropriate dosage methods and predicts the duration of drug effectiveness together with its potential side effects.

5.1 Bioavailability and Absorption

The intravenous administration of ketamine results in complete bioavailability which achieves peak plasma levels at the infusion completion point that occurs after 40 minutes. The mean absolute bioavailability of intranasal esketamine is approximately 48% because the nasal mucosa absorption together with swallowing of the solution enables its entry into the bloodstream [19]. Peak plasma concentrations Tmax are typically reached between 20 to 40 minutes post-dose.

5.2 Distribution and Metabolism

The two chemicals have high lipid solubility which enables them to quickly pass through the blood-brain barrier. The substances spread throughout the human body because they possess extensive distribution volumes. The liver processes ketamine through various metabolic pathways which primarily involve cytochrome P450 enzymes CYP2B6 and CYP3A4. The primary metabolic route begins with N-demethylation which produces norketamine an active metabolite that exhibits reduced NMDA receptor binding strength [20].

The intravenous administration of ketamine results in a brief distribution half-life which lasts approximately 10 to 15 minutes during the first alpha phase and an elimination half-life that lasts between 2 and 3 hours. Esketamine nasal spray displays a terminal half-life that extends from 7 to 12 hours because of its sustained absorption process which occurs through the nasal cavity and subsequent tissue redistribution [21].

6. Clinical evidence

6.1 Ketamine in Depression

The initial proof-of-concept research by Berman et al. 2000 and its later verification by Zarate et al. 2006 conducted their study using a sub-anesthetic dosage of 0.5 mg/kg of IV ketamine which they administered during a 40-minute period. The research showed that subjects experienced a significant decrease in MADRS scores which reached their lowest point between 110 and 240 minutes after treatment [22].

The meta-analysis which examined single-dose IV ketamine studies found that TRD populations showed a response rate between 50 and 70 percent after 24 hours of treatment [23]. The effects provide strong benefits which last between three to seven days. The institution of multiple infusion scheduling which consists of six infusions spread across two to three weeks has shown that this method produces additional advantages which help maintain remission status [24].

6.2 Esketamine Trials (The TRANSFORM and SUSTAIN Programs)

The complete Phase III program delivered all essential information which resulted in the government approval of esketamine. The researchers carried out their study through two different double-blind RCTs named TRANSFORM- 1 and TRANSFORM-2 which evaluated the impact of esketamine together with a new oral antidepressant against the placebo nasal spray treatment plus oral AD[25].

The TRANSFORM-2 results showed that at day 28 the esketamine group demonstrated a statistically significant improvement in their MADRS score. The TRANSFORM-1 results showed no statistical significance because of heightened placebo response rates but the study demonstrated a beneficial pattern. The study examined participants who reached the age of 65 years or older. The researchers used treatment effects which reached significance but the study failed to demonstrate any primary outcome through statistical testing to help decide treatment methods for elderly patients[26]. The research study SUSTAIN-1 aimed to stop patients from experiencing relapses. The study participants who reached remission during the induction period were assigned to two groups which either continued esketamine treatment or received placebo. Esketamine treatment led to a 51 percent decrease in relapse risk for remitters while responders experienced a 70 percent decline in their relapse risk when compared to placebo[27].

6.3 Anti-Suicidal Efficacy

Both agents have shown proven abilities to prevent suicide attempts. The ASPIRE I and II trials tested the effectiveness of esketamine on MDD patients who showed immediate suicidal danger. The studies showed that both depressive symptoms and suicidal thoughts experienced a 24-hour reduction which created specific treatment guidelines for this particular group[28]. The meta-analyses showed that IV ketamine treatment produced immediate decreases of suicidal thoughts while other depressive symptoms remained unchanged according to the studies[29].

7. Indications & Patient Selection

The rational use of these agents requires strict adherence to indication criteria to maximize benefit and minimize risk.

• Primary Indications:

Treatment-Resistant Depression (TRD): Adults who have not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode [30].

MDD with Acute Suicidal Ideation/Behavior: The treatment provides immediate symptom relief which occurs during hospital admission and standard medical treatment[28].

Contraindications:

• Aneurysmal vascular disease (due to transient blood pressure elevation).
• History of intracerebral hemorrhage.
• Hypersensitivity to ketamine/esketamine.
• Active psychosis or history of psychotic disorders (relative contraindication due to dissociative effects) [31].

8. Dosing & administration

8.1 IV Ketamine (Off-Label)

The standard protocol requires an intravenous infusion of 0.5 mg/kg to be given over a time period of 40 minutes. The standard protocol requires Induction to be administered as two to three weekly infusions during three total weeks which results in six total infusions. The tapering process for maintenance starts with weekly treatments which change to biweekly and then monthly applications based on patient evaluations[32].

8.2 Intranasal Esketamine (Spravato)

The medical community does not agree about how long maintenance treatment should continue. The drug needs to be administered in a certified healthcare facility where medical staff can supervise its application. The drug delivers therapeutic effects through its nasal spray devices which contain 28 mg of active ingredient for single use. The drug provides two dosing options which include 56 mg and 84 mg. The treatment program requires patients to attend sessions two times each week during the first four weeks. The treatment program requires patients to attend sessions once each week during the period from week five until week eight. The treatment program allows patients to receive treatment either once a week or once every two weeks from week nine onward [33]. The Risk Evaluation and Mitigation Strategy REMS requires mandatory implementation of the program. Patients require observation for a minimum duration of 2 hours after receiving their treatment until they achieve clinical stability [34].

9. Safety & Adverse Effects

The safety profile of NMDA antagonists shows different results than the safety profile of standard antidepressant medications.

• Dissociation and psychotomimetic effects:

Dissociative symptoms together with psychotic-like symptoms show different results from each other through their first 30 minutes. Around 60 to 75 percent of patients experience dissociation derealization or perceptual alterations during the administration window. The effects reach their highest point at 40 minutes but vanish completely by 90 minutes. The treatment causes mild disturbances which do not reach a level that requires patients to stop their medication but patients need a silent place with supportive help to finish their medication.

• Hemodynamic Changes:

The system experiences temporary height increases which result in systolic blood pressure rising between 10 and 20 mmHg and diastolic blood pressure rising between 10 and 20 mmHg. The sympathetic nervous system activates which causes these blood pressure fluctuations. Blood pressure measurements need to occur at three specific times which include the first dose and 40 minutes after that and just before the patient departs the medical facility [35]. Hypertensive crises are rare but possible.

• Genitourinary Toxicity (Ketamine Cystitis):

The development of ulcerative cystitis which includes frequent urination and urgent need to urinate and blood in urine results from chronic high-dose recreational use of ketamine[36]. The clinical trials (TRANSFORM/SUSTAIN) showed a low cystitis occurrence rate which resulted in mostly mild cases. The requirement for ongoing monitoring applies to maintenance patients because the toxic threshold for chronic low-dose treatment remains unknown [37].

• Cognitive safety:

The research conducted on human subjects demonstrated that rodents develop neurotoxic effects when they receive therapeutic doses which lead to the development of Olney's lesions. The one-year study which tested esketamine demonstrated that cognitive abilities remained stable while cognitive functions improved when patients showed less severe depression symptoms [38].

10. Abuse Potential & Ethical Issues

The recreational drug known as "Special K" exists as a recognized street drug. The actual dangers which emerge from using the drug for therapeutic purposes to obtain it and become addicted to it currently exist as unproven possibilities. The distribution system for Esketamine exists as a controlled access system which operates under REMS requirements to solve this particular problem. The patients administer the drug themselves under healthcare provider supervision because they do not take it home.

Most users experience mild or nonexistent withdrawal symptoms from therapeutic doses while they show intense "craving" behavior during abusive situations [39].

The high treatment expenses together with the requirement for multiple clinic visits create challenges which prevent patients from receiving needed medical treatment. The organization needs a complete management system to deal with all the risks because people tend to avoid psychosocial treatments after getting immediate emotional relief.

11. Comparison with Other Rapid Antidepressants

New rapid-acting antidepressant drugs have entered the market since recent times.

• Brexanolone: An intravenous neurosteroid which treats postpartum depression. The treatment requires patients to remain in the hospital for 60 hours because the system needs continuous medication delivery which resembles ketamine therapy [40].
• Psilocybin: The substance is undergoing testing in Phase II/III clinical trials. Psilocybin therapy usually involves one or two macroscopic doses with intense psychotherapy. In psilocybin therapy the main element for healing comes from the psychedelic experience while ketamine treatment produces dissociation as an unintended outcome [41].
• ECT (Electroconvulsive Therapy): The treatment maintains its position as the TRD treatment standard with highest proven effectiveness. The results from head-to-head trials (e.g., KetECT) show that ketamine provides equal effectiveness to ECT for quick symptom relief but ECT results in higher remission rates among patients with psychotic depression [42].

12. Role of Pharmacists & Nurses

The interdisciplinary team is essential for executing these therapies in a secure manner.

• Nurses: During the dissociative phase they monitor physical health through blood pressure and oxygen saturation tests while providing psychological support to patients. The staff members perform the "sitter" function which safeguards patients from experiencing falls and agitation.
• Pharmacists: Create legal custody procedures which ensure that patients receive protection through adherence to REMS regulations. Their work includes making intravenous IV solutions while assessing drug interactions between lamotrigine and benzodiazepines and other medications which decrease ketamine effectiveness. They guide patients through their upcoming medical experiences.[43].

13. Limitations of Current Evidence

• Long term safety: The existing research shows two remaining gaps despite all current excitement. The controlled studies provide safety data which extends through one year. The effects of years of maintenance treatment on the bladder and brain are unknown.
• Comparison Efficacy: Research only provides a limited number of studies which directly compare the effectiveness of IV ketamine against Intranasal esketamine. A recent systematic review suggests IV ketamine might have higher efficacy but esketamine offers the legitimacy of FDA approval and insurance coverage [44].
• Functional Outcomes: The data shows symptom scores improve but the information about work return and social activity performance remains less developed.

14. Future Directions

The future of glutamatergic therapy lies in optimizing delivery and finding agents with fewer side effects.

• Oral Ketamine: The development of extended-release oral formulations is currently at the testing stage to make treatment more easily available [45].
• Novel agents: The discovery of new therapeutic agents emerges from ongoing research which focuses on developing drugs that bind to particular protein components and NR2B blockers and mTOR inhibitors to create separate antidepressant effects which induce hallucinations.
• Biomarkers: The medical field needs to develop EEG and blood biomarkers which include baseline BDNF levels as essential tools to determine patient responses to ketamine treatment [46].

CONCLUSION

The development of ketamine and esketamine marks the most important progress in psychopharmacology since the last several decades. These drugs enable treatment for patients who experience treatment-resistant depression because they have not responded to standard monoaminergic therapies. The clinical evidence supports their rapid efficacy, particularly in acute crises and TRD. The drug requires careful monitoring for its cardiovascular and dissociative side effects which must be evaluated through strict monitoring protocols to determine its advantages and disadvantages. The maximum therapeutic effect of these agents will occur through their use in a complete bio- psycho-social treatment system which ensures patient security instead of using them as single treatments for various conditions.

REFERENCES

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. https://pubmed.ncbi.nlm.nih.gov/29477251/
2. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO; 2017. https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2- eng.pdf
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. https://pubmed.ncbi.nlm.nih.gov/17074942/
4. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. https://pubmed.ncbi.nlm.nih.gov/10686270/
5. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72. https://pubmed.ncbi.nlm.nih.gov/23042884/
6. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. https://pubmed.ncbi.nlm.nih.gov/31166571/
7. Kang HJ, Voleti B, Hajszan T, et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med. 2012;18(9):1413-1417. https://pubmed.ncbi.nlm.nih.gov/22885997/
8. Diazgranados N, Ibrahim L, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605-1611. https://pubmed.ncbi.nlm.nih.gov/21190635/
9. Conway CR, George MS, Sackeim HA. Toward an Evidence-Based, Operational Definition of Treatment- Resistant Depression: When Enough Is Enough. JAMA Psychiatry. 2017;74(1):9-10. https://pubmed.ncbi.nlm.nih.gov/27783815/
10. Mion G. History of anaesthesia: The ketamine story - past, present and future. Eur J Anaesthesiol. 2017;34(9):571-575. https://pubmed.ncbi.nlm.nih.gov/28777174/
11. Henter ID, Zanos P, Gould TD, Zarate CA Jr. Ketamine's Mechanism of Action: A Path to Rapid-Acting Antidepressants. Depress Anxiety. 2021;38(5):518-527. https://pubmed.ncbi.nlm.nih.gov/33932267/
12. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27(43):11496-11500. https://pubmed.ncbi.nlm.nih.gov/17959792/
13. Abdallah CG, Adams TG, Kelmendi B, et al. Ketamine's mechanism of action: a review of the preclinical and clinical literature. Focus (Am Psychiatr Publ). 2016;14(2):216-227. https://pubmed.ncbi.nlm.nih.gov/31975806/
14. Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481-486. https://pubmed.ncbi.nlm.nih.gov/27144355/
15. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964. https://pubmed.ncbi.nlm.nih.gov/20724638/
16. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73(12):1133-1141. https://pubmed.ncbi.nlm.nih.gov/23541000/
17. Highland JN, Zanos P. Mechanisms of action of ketamine and its metabolites. Neuropharmacology. 2019;149:8-23. https://pubmed.ncbi.nlm.nih.gov/30660634/
18. Yang Y, Cui Y, Sang K, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554(7692):317-322. https://pubmed.ncbi.nlm.nih.gov/29446381/
19. Perez-Ruixo C, Rossenu S, Zannikos P, et al. Population Pharmacokinetics of Esketamine Nasal Spray in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin Pharmacokinet. 2021;60(4):501-517. https://pubmed.ncbi.nlm.nih.gov/32894451/
20. Zarate CA Jr, Brutsche N, Laje G, et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72(4):331-338. https://pubmed.ncbi.nlm.nih.gov/22579306/
21. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370-380. https://pubmed.ncbi.nlm.nih.gov/23594247/
22. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. https://pubmed.ncbi.nlm.nih.gov/16894061/
23. Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D- aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459-1472. https://pubmed.ncbi.nlm.nih.gov/26809270/
24. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256. https://pubmed.ncbi.nlm.nih.gov/23245766/
25. Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/
26. Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121-141. https://pubmed.ncbi.nlm.nih.gov/31628045/
27. Wajs E, Aluisio L, Holder R, et al. Long-term cognitive safety of intranasal esketamine in patients with treatment-resistant depression: results from the SUSTAIN-2 study. Int Clin Psychopharmacol. 2020;35(5):269-278. https://pubmed.ncbi.nlm.nih.gov/32779951/
28. Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018;175(7):620-630. https://pubmed.ncbi.nlm.nih.gov/29656663/
29. Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150-158. https://pubmed.ncbi.nlm.nih.gov/28969441/
30. Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the Medicare population. AHRQ Technology Assessments. 2018. https://pubmed.ncbi.nlm.nih.gov/30285375/
31. Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405. https://pubmed.ncbi.nlm.nih.gov/28249076/
32. Andrade C. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? J Clin Psychiatry. 2017;78(7):e852-e857. https://pubmed.ncbi.nlm.nih.gov/28858448/
33. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized Double-Blind Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. https://pubmed.ncbi.nlm.nih.gov/31292615/
34. Swainson J, Thomas RK, Archer H, et al. Esketamine for treatment resistant depression. Expert Rev Neurother. 2019;19(10):899-911. https://pubmed.ncbi.nlm.nih.gov/31333061/
35. Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65-78. https://pubmed.ncbi.nlm.nih.gov/28757132/
36. Chu PS, Ma WK, Wong SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 2008;102(11):1616-1622. https://pubmed.ncbi.nlm.nih.gov/18710445/
37. Sassano-Higgins S, Baron D, Juarez G, et al. A review of ketamine abuse and diversion. Depress Anxiety. 2016;33(8):718-727. https://pubmed.ncbi.nlm.nih.gov/27299903/
38. Chen C, Ke Q, Fu X, et al. A review of the safety and efficacy of ketamine in the treatment of major depressive disorder. Gen Psychiatr. 2018;31(2):e100013. https://pubmed.ncbi.nlm.nih.gov/31193359/
39. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction. 2009;104(1):77-87. https://pubmed.ncbi.nlm.nih.gov/19133891/
40. Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390(10093):480-489. https://pubmed.ncbi.nlm.nih.gov/28619476/
41. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment- resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. https://pubmed.ncbi.nlm.nih.gov/27210031/
42. Phillips JL, Sehl T, Tso R, et al. Ketamine-electroconvulsive therapy (ECT) interactions: a systematic review and meta-analysis. J ECT. 2017;33(1):7-18. https://pubmed.ncbi.nlm.nih.gov/27649567/
43. Fancy S, Kim JG. Esketamine: A Novel Option for Treatment-Resistant Depression. Ann Pharmacother. 2020;54(7):696-702. https://pubmed.ncbi.nlm.nih.gov/32019316/
44. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542-555. https://pubmed.ncbi.nlm.nih.gov/33065824/
45. Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214(1):20-26. https://pubmed.ncbi.nlm.nih.gov/30298816/
46. Leal GC, Bandeira ID, Correia-Melo FS, et al. Intravenous ketamine for bipolar depression: a systematic review and meta-analysis. Expert Rev Neurother. 2020;20(10):1049-1056. https://pubmed.ncbi.nlm.nih.gov/32772591/